FDA 2024: Watch For Trial-Diversity Guidance, Final Quality Systems Rewrite
Industry observers at RAPS Convergence in Montreal last week said the FDA’s agenda for 2024 is likely to include increased emphasis on MDUFA goals, enhanced cybersecurity requirements, the new QMSR, and more.
You may also be interested in...
The US FDA is giving sponsors a grace period of six months before it will issue “refuse to accept” decisions for premarket submissions for cyber devices that lack the information required under recent cyber amendments.
This exclusive infographic shows new review timelines the FDA announced for FY 2023 now that MDUFA V has been ratified.
The US agency has outlined steps industry can take to ensure clinical trials include a broader representation of underrepresented racial and ethnic groups.